Moderate Growth in the Epilepsy Market is Expected from 2012 to 2022, According to a New Study on ASDReports

Friday 3 October 2014, Amsterdam

The global epilepsy market was valued at an estimated $4.2 billion in 2012. GlobalData expects the market to grow to $5.35 billion by 2022, with more than 50% of sales coming from the US. Major drivers of market growth over this forecast period will include:

• Introduction of novel antiepileptic drugs (AEDs) with higher prices in the US and European Union (EU)
• Introduction of the newer drugs into the Asian market, particularly in Japan

• Increasing access to epilepsy pharmacotherapy by the populations of India and China 

Major barriers to the growth of the epilepsy market will include:

• A crowded marketplace, which currently comprises more than 20 AEDs, many of which are available in generic form, resulting in individual drugs struggling to distinguish themselves
• Concerns over decreasing healthcare costs as part of government austerity measures, which will impede market growth, particularly in Europe
• Generic erosion of branded drug sales following small-molecule patent and marketing exclusivity expiries, particularly affecting Vimpat (lacosamide) and Lyrica (pregabalin)